Personalized antibiotics may beat standard therapy for stubborn stomach bug

NCT ID NCT05332444

Recruiting now Disease control Sponsor: National Taiwan University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether choosing antibiotics based on lab tests of the bacteria works better than standard antibiotic combinations for people whose H. pylori infection hasn't been cured before. About 450 adults will receive either a tailored or standard regimen for 14 days. The goal is to see which approach clears the infection more effectively and with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proton pump inhibitor (rabeprazole) and antibiotics (amoxicillin, clarithromycin, levofloxacin, metronidazole, tetracycline) plus bismuth
What this could lead to: If successful, this could show that tailoring antibiotics to the specific bacteria is more effective than standard treatments for stubborn H. pylori infections.
What could go wrong: This is a Phase 4 trial, so the treatments are already approved, but results may not apply to all populations. Antibiotic resistance could still limit success.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Helicobacter pylori infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HELICOBACTER PYLORI INFECTION

Contacts and locations

Locations

National Taiwan University Hospital
RECRUITING

Taipei, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.